What SEC filings does Nektar Therapeutics submit to the SEC?

Nektar Therapeutics (NKTR) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about NKTR?

A Form 4 for NKTR discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Nektar Therapeutics?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for NKTR?

The 10-K is Nektar Therapeutics's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all NKTR SEC filings directly on EDGAR?

You can view all historical Nektar Therapeutics filings on the SEC EDGAR company page for NKTR. Each filing card on this page links directly to the original SEC document.

How often does Nektar Therapeutics file with the SEC?

Nektar Therapeutics files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling NKTR shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

NKTR SEC Filing News — Nektar Therapeutics

Latest SEC filings for Nektar Therapeutics (NKTR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-01.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat …

Sector: Healthcare Industry: Biotechnology Market Cap: $1.2B CIK: 906709

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for NKTR currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

NKTR Filing Activity Snapshot 2026-06-17 — 2026-10-01

Insider Transactions (Form 4)

0 buys vs 5 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.22M

ROBIN HOWARD W (Director, President & CEO) · 2026-06-18

20,000 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Nektar Therapeutics.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 7 compensation award and 5 open-market sale. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×5: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Compensation award Tax / Compensation Filing 2026-09-25

NKTR insider Form 4 filed for equity award, exercise, or tax withholding

WHITFIELD ROY A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,000	—	—
`A`	Compensation award derivative · Stock Option	4,000	—	—

Filing: Form 4 (Insider Transaction) Insider: WHITFIELD ROY A (Director) Shares: 2,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-25

NKTR insider Form 4 filed for equity award, exercise, or tax withholding

GREER R SCOTT (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,000	—	—
`A`	Compensation award derivative · Stock Option	4,000	—	—

Filing: Form 4 (Insider Transaction) Insider: GREER R SCOTT (Director) Shares: 2,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-25

NKTR insider Form 4 filed for equity award, exercise, or tax withholding

CHESS ROBERT (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,000	—	—
`A`	Compensation award derivative · Stock Option	4,000	—	—

Filing: Form 4 (Insider Transaction) Insider: CHESS ROBERT (Director) Shares: 2,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-25

NKTR insider Form 4 filed for equity award, exercise, or tax withholding

Brainard Diana (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,000	—	—
`A`	Compensation award derivative · Stock Option	4,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Brainard Diana (Director) Shares: 2,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-25

NKTR insider Form 4 filed for equity award, exercise, or tax withholding

Ajer Jeffrey Robert (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,000	—	—
`A`	Compensation award derivative · Stock Option	4,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Ajer Jeffrey Robert (Director) Shares: 2,000

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-20

NKTR insider Zalevsky Jonathan (Chief R&D Officer) sold 186 shares (~$13.4K)

Zalevsky Jonathan, listed as Chief R&D Officer at NEKTAR THERAPEUTICS, reported an open-market sale of 186 NKTR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	186	$71.98	$13.4K

Filing: Form 4 (Insider Transaction) Insider: Zalevsky Jonathan (Chief R&D Officer) Shares: 186 Est. Value: $13.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-20

NKTR insider ROBIN HOWARD W (Director, President & CEO) sold 418 shares (~$30.1K)

ROBIN HOWARD W, listed as Director, President & CEO at NEKTAR THERAPEUTICS, reported an open-market sale of 418 NKTR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	418	$71.98	$30.1K

Filing: Form 4 (Insider Transaction) Insider: ROBIN HOWARD W (Director, President & CEO) Shares: 418 Est. Value: $30.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-24

NKTR insider Form 4 filed for equity award, exercise, or tax withholding

Zalevsky Jonathan (Chief R&D Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option	16,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Zalevsky Jonathan (Chief R&D Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-24

NKTR insider Form 4 filed for equity award, exercise, or tax withholding

ROBIN HOWARD W (Director, President & CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option	57,200	—	—

Filing: Form 4 (Insider Transaction) Insider: ROBIN HOWARD W (Director, President & CEO)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-02

NKTR insider Zalevsky Jonathan (Chief R&D Officer) sold 5,681 shares (~$397.7K)

Zalevsky Jonathan, listed as Chief R&D Officer at NEKTAR THERAPEUTICS, reported an open-market sale of 5,681 NKTR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,681	$70.00	$397.7K

Filing: Form 4 (Insider Transaction) Insider: Zalevsky Jonathan (Chief R&D Officer) Shares: 5,681 Est. Value: $397.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-18

NKTR insider ROBIN HOWARD W (Director, President & CEO) sold 20,000 shares (~$1.22M)

ROBIN HOWARD W, listed as Director, President & CEO at NEKTAR THERAPEUTICS, reported an open-market sale of 20,000 NKTR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,303	$59.97	$318.0K
`S`	Open-market sale	4,697	$60.71	$285.2K
`S`	Open-market sale	5,500	$60.81	$334.5K
`S`	Open-market sale	4,500	$61.65	$277.4K

Filing: Form 4 (Insider Transaction) Insider: ROBIN HOWARD W (Director, President & CEO) Shares: 20,000 Est. Value: $1.22M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-17

NKTR insider Zalevsky Jonathan (Chief R&D Officer) sold 5,538 shares (~$336.2K)

Zalevsky Jonathan, listed as Chief R&D Officer at NEKTAR THERAPEUTICS, reported an open-market sale of 5,538 NKTR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,538	$60.71	$336.2K

Filing: Form 4 (Insider Transaction) Insider: Zalevsky Jonathan (Chief R&D Officer) Shares: 5,538 Est. Value: $336.2K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Nektar Therapeutics has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-18

NKTR Form 144 filed for proposed insider sale by Zalevsky Jonathan (186 shares) ~$13.4K

Zalevsky Jonathan filed a Form 144 with the SEC indicating intent to sell NKTR (NEKTAR THERAPEUTICS) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Zalevsky Jonathan Shares: 186 Est. Value: $13.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-18

NKTR Form 144 filed for proposed insider sale by ROBIN HOWARD W (418 shares) ~$30.1K

ROBIN HOWARD W filed a Form 144 with the SEC indicating intent to sell NKTR (NEKTAR THERAPEUTICS) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ROBIN HOWARD W Shares: 418 Est. Value: $30.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-30

NKTR Form 144 filed for proposed insider sale by JONATHAN ZALEVSKY (5,681 shares) ~$371.5K

JONATHAN ZALEVSKY filed a Form 144 with the SEC indicating intent to sell NKTR (NEKTAR THERAPEUTICS) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JONATHAN ZALEVSKY Shares: 5,681 Est. Value: $371.5K

View on SEC EDGAR → Open Filing Document →

Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Nektar Therapeutics. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-01

NKTR filed 8-K — material company event

NEKTAR THERAPEUTICS filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-25

NKTR filed 8-K — material company event

NEKTAR THERAPEUTICS filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-08

NKTR filed 8-K — material company event

NEKTAR THERAPEUTICS filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-13

NKTR filed 8-K — material company event

NEKTAR THERAPEUTICS filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Nektar Therapeutics.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-14

NKTR filed Quarterly Report (10-Q)

NEKTAR THERAPEUTICS filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Nektar Therapeutics's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on NKTR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — NKTR SEC Filings

More Tools for NKTR

NKTR Full Stock Analysis NKTR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper NKTR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the NKTR stock analysis page.

NKTR Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer